Senores Pharma Logs Record Q2, Marks Ninth Quarter Of Double-Digit Growth

What happened

Senores Pharmaceuticals reported record second-quarter revenue of Rs 192.3 crore, up 24.9 per cent from a year earlier, and EBITDA of Rs 58 crore, up 38 per cent. It was the company's ninth straight quarter of double-digit growth.

Confirmed

Global impact / market context

Faster profit growth than revenue growth means the company kept more profit per sale, which means sales are converting into earnings more efficiently. That supports cash generation and could fund research, new products and expansion without relying as heavily on borrowed money.

Analyst inference

Growth came mainly from regulated markets, where revenue rose 27.9 per cent to Rs 136.7 crore. Investors often treat steady multi-quarter growth and widening profit per sale as signs of durable demand, so this result may strengthen expectations for the company's shares.

Analyst inference

What to watch

1. Cash generated from operations was Rs 38 crore in the second quarter, versus Rs 31 crore a year earlier, so watch whether cash keeps rising alongside reported profit. Confirmed
2. Watch whether Senores can keep expanding its product portfolio and regulated-market sales, since these drove growth, and whether new drug approvals add revenue. Proposed
3. Watch EBITDA margin, which widened about 290 basis points, meaning profit per sale improved; if costs rise or growth slows, that gain could reverse. Analyst inference

Evidence

• Original source link unavailable